Blacklight

Evaluating clinical research : all that glitters is not gold /

Title:
Evaluating clinical research : all that glitters is not gold /
Author:
Furberg, Bengt.
Published:
New York : c2007.
Format:
Book
Institution:
New England College of Optometry
Contents:
1 What is the purpose of this book? -- 2 Why is benefit-to-harm balance essential to treatment decisions? -- 3 What are the strengths of randomized controlled clinical trials? -- 4 What are the weaknesses of randomized controlled clinical trials? -- 5 Do meta-analyses provide the ultimate truth? -- 6 What are the strengths of observational studies? -- 7 What are the weaknesses of observational studies? -- 8 Were the scientific questions stated in advance? -- 9 Were the treatment groups comparable initially? -- 10 Why is blinding/masking so important? -- 11 How is symptomatic improvement measured? -- 12 Is it really possible to assess quality of life? -- 13 What is the value of biologic markers in drug evaluation? -- 14 How are adverse drug reactions measured? -- 15 How representative are study subjects in clinical trials? -- 16 What happened to the study subjects who disappeared from the analysis? -- 17 How reliable are active-control trials? -- 18 How informative are composite outcomes? -- 19 Do changes in biologic markers predict clinical benefit? -- 20 How trustworthy are the authors? -- 21 Does publication in a reputable scientific journal guarantee quality? -- 22 Is it necessary to be a biostatistician to interpret scientific data? -- 23 Are all drugs of a class interchangeable? -- 24 How much confidence can be placed on economic analysis? -- 25 How should I handle the massive flow of information? -- 26 How well is research translated into clinical care?

Online access:
No online access
Library holdings:
NECO Book Stacks
R853.C55 .F87 2007Available